PMID- 18029231
OWN - NLM
STAT- MEDLINE
DCOM- 20080317
LR  - 20080213
IS  - 1471-4914 (Print)
IS  - 1471-4914 (Linking)
VI  - 13
IP  - 11
DP  - 2007 Nov
TI  - Matrix metalloproteinase dysregulation in HIV infection: implications for 
      therapeutic strategies.
PG  - 449-59
AB  - The emerging role of immune activation and inflammation in the pathogenesis of 
      human immunodeficiency virus (HIV) disease has stimulated the search for new 
      approaches for managing HIV infection. Recent evidence suggests that an imbalance 
      between matrix metalloproteinases (MMPs) and endogenous tissue inhibitors of MMPs 
      (TIMPs) might contribute to HIV-associated pathology by inducing remodelling of 
      the extracellular matrix. Here, we discuss the evidence and the potential 
      mechanisms for altered MMP or TIMP function in HIV infection and disease. 
      Furthermore, we outline the possible medical implications for the use of 
      compounds that target MMP activity, and we propose that antiretroviral drugs, 
      particularly HIV protease inhibitors (PIs), and compounds with anti-inflammatory 
      properties, such as statins, natural omega-3 fatty acids and tetracyclines, which 
      inhibit MMP function, might represent useful therapeutic approaches to mitigate 
      potential MMP-related damage during HIV infection.
FAU - Mastroianni, Claudio M
AU  - Mastroianni CM
AD  - Department of Infectious and Tropical Diseases, Sapienza University of Rome, 
      Ospedale S. Maria Goretti, 04100 Latina, Italy. claudio.mastroianni@uniroma1.it
FAU - Liuzzi, Grazia M
AU  - Liuzzi GM
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20071029
PL  - England
TA  - Trends Mol Med
JT  - Trends in molecular medicine
JID - 100966035
RN  - 0 (Anti-HIV Agents)
RN  - 0 (HIV Protease Inhibitors)
RN  - 0 (Tissue Inhibitor of Metalloproteinases)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
SB  - IM
MH  - Anti-HIV Agents/pharmacology/therapeutic use
MH  - HIV Infections/*metabolism/pathology/prevention & control
MH  - HIV Protease Inhibitors/pharmacology/therapeutic use
MH  - Humans
MH  - Matrix Metalloproteinases/*metabolism
MH  - Models, Biological
MH  - Signal Transduction/drug effects
MH  - Tissue Inhibitor of Metalloproteinases/metabolism
RF  - 90
EDAT- 2007/11/22 09:00
MHDA- 2008/03/18 09:00
CRDT- 2007/11/22 09:00
PHST- 2007/05/29 00:00 [received]
PHST- 2007/09/10 00:00 [revised]
PHST- 2007/09/12 00:00 [accepted]
PHST- 2007/11/22 09:00 [pubmed]
PHST- 2008/03/18 09:00 [medline]
PHST- 2007/11/22 09:00 [entrez]
AID - S1471-4914(07)00181-5 [pii]
AID - 10.1016/j.molmed.2007.09.001 [doi]
PST - ppublish
SO  - Trends Mol Med. 2007 Nov;13(11):449-59. doi: 10.1016/j.molmed.2007.09.001. Epub 
      2007 Oct 29.